Susan Costantini (@susancostantin5) 's Twitter Profile
Susan Costantini

@susancostantin5

Dr. Susan Costantini is a Chemistry and has a Specialization in Clinical Pathology and Biochemistry. She works at @istitutotumori

ID: 1496796547442483207

calendar_today24-02-2022 10:38:16

18 Tweet

13 Takipçi

32 Takip Edilen

alfredo budillon (@alfredobudillon) 's Twitter Profile Photo

Just online ! Our study on the potential role as #biomarker of #Selenoprotein #SelenoS and #VCP/p97 in #TNBC #breastcancer #Istitutotumorinapoli #iomicuroalsud mdpi.com/1471536 #mdpicancers via Cancers MDPI

Cameron Thrash (@jcamthrash) 's Twitter Profile Photo

COMMIT: Consideration of metabolite leakage and community composition improves microbial community reconstructions dx.plos.org/10.1371/journa…

alfredo budillon (@alfredobudillon) 's Twitter Profile Photo

Just printed ! A comprhensive book on #Metabolomics, the profiling of #metabolites in biofluids, cells and tissues, where with Susan Costantini we wrote a chapter on its application in Oncology. elsevier.com/books/metabolo…

Just printed ! A comprhensive book on #Metabolomics, the profiling of #metabolites in biofluids, cells and tissues, where with <a href="/SusanCostantin5/">Susan Costantini</a> we wrote a chapter on its application in Oncology. elsevier.com/books/metabolo…
alfredo budillon (@alfredobudillon) 's Twitter Profile Photo

#AACR2022 IMPROVE study Abstract #3503. Presentation Date and Time: 6/6/2022, 10:45 AM CDT Location: McCormick Place: Arie Crown Theater Antonio

#AACR2022 IMPROVE study Abstract #3503.
Presentation Date and Time: 6/6/2022, 10:45 AM CDT
Location: McCormick Place: Arie Crown Theater <a href="/AvalloneAnt/">Antonio</a>
alfredo budillon (@alfredobudillon) 's Twitter Profile Photo

#ASCO2022 We just presented IMPROVE study results : Intermittent FOLFIRI/PANITUMUMAB in RAS/BRAF wt unresectable mCRC showed a mPFS on treatment of 17.1 vs 13.2 (20.2 vs 13 in left sided) months vs standard continous exposure, with less skin related toxicities #crcsm Antonio

#ASCO2022 We just presented IMPROVE study results : Intermittent FOLFIRI/PANITUMUMAB in RAS/BRAF wt unresectable mCRC showed a mPFS on treatment of 17.1 vs 13.2 (20.2 vs 13 in left sided) months vs standard continous exposure, with less skin related toxicities #crcsm <a href="/AvalloneAnt/">Antonio</a>
AIOM (@aiomtweet) 's Twitter Profile Photo

Registrati al webinar “Immunoncologia: la nuova era inizia dal melanoma”, il 16 giugno alle 13. Clicca qui: us02web.zoom.us/webinar/regist… #AIOM #webinar #immunoncologia

Registrati al webinar “Immunoncologia: la nuova era inizia dal melanoma”, il 16 giugno alle 13.

Clicca qui: us02web.zoom.us/webinar/regist…

#AIOM #webinar #immunoncologia
alfredo budillon (@alfredobudillon) 's Twitter Profile Photo

Proud to have been appointed by the Italian Ministry of health as new Scientific Director of Istituto Nazionale Tumori Pascale Pascale of Naples, Italy, Where I have been doing my research work in the last 25 years

alfredo budillon (@alfredobudillon) 's Twitter Profile Photo

Just Online: here we showed that inhibition of #authophagy with #chloroquine overcome resistance to PI3K/AKT inhibitors plus paclitaxel in #TNBC models, suggesting that the evaluation of such combinations in clinical trials is warranted. BMC rdcu.be/cQRKO

Just Online: here we showed that inhibition of #authophagy with #chloroquine overcome resistance to PI3K/AKT inhibitors plus paclitaxel in #TNBC models, suggesting that the evaluation of such combinations in clinical trials is warranted. <a href="/BioMedCentral/">BMC</a> rdcu.be/cQRKO
Journal of Clinical Oncology (@jco_asco) 's Twitter Profile Photo

🚨 #JCO #SpecialSeriesReview: Summary of recent data on the use of #immunotherapy in upper GI cancers and clinical implications Read more 👉 fal.cn/3qCZ0 #EsophagealCancer #GastricCancer #esocsm #immunoonc #stcsm Nataliya Uboha

🚨 #JCO #SpecialSeriesReview: Summary of recent data on the use of #immunotherapy in upper GI cancers and clinical implications

Read more 👉 fal.cn/3qCZ0 #EsophagealCancer #GastricCancer #esocsm #immunoonc #stcsm <a href="/NataliyaUboha/">Nataliya Uboha</a>
Immunometabolism Network (@immunomet) 's Twitter Profile Photo

Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment #immunometabolism bit.ly/3zGVgpS

Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment
#immunometabolism

bit.ly/3zGVgpS
Immunometabolism Network (@immunomet) 's Twitter Profile Photo

New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment #immunometabolism bit.ly/3AihIHy

New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment
#immunometabolism
bit.ly/3AihIHy
Immunometabolism Network (@immunomet) 's Twitter Profile Photo

Fascinating! PARC, an adipokine, and immunometabolic checkpoint of macrophage inflammatory and interferon response in age-related metabolic and functional decline. #immunometabolism #metabolism #aging bit.ly/3bQRouL

Fascinating! 
PARC, an adipokine, and immunometabolic checkpoint of macrophage inflammatory and interferon response in age-related metabolic and functional decline.

#immunometabolism #metabolism #aging 

bit.ly/3bQRouL
Stuart Cook (@stuartacook1) 's Twitter Profile Photo

LKB1 (STK11), a master metabolic kinase, is inhibited by IL11. The most direct example of immunometabolism to date ⁦Immunometabolism Network⁩? This links ERK (trametinib) to AMPK (metformin) and mTOR (rapamycin) - in one pathway ⁦⁦Nathan S. Cheng thinks you should work on aging.⁩ cell.com/iscience/fullt…

alfredo budillon (@alfredobudillon) 's Twitter Profile Photo

Just online Frontiers - Oncology ! Plasma #metabolomics, #lipidomics and #cytokinomics profiling predict disease recurrence in metastatic colorectal cancer patients undergoing liver resection frontiersin.org/articles/10.33… Istituto Nazionale Tumori Pascale #mCRC